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Abstract
Timed degradation of the cyclin-dependent kinase inhibitor p27Kip1 by the E3 ubiquitin ligase F-box protein SKP2 is critical
for T-cell progression into cell cycle, coordinating proliferation and differentiation processes. SKP2 expression is regulated by
mitogenic stimuli and by Notch signaling, a key pathway in T-cell development and in T-cell acute lymphoblastic leukemia
(T-ALL); however, it is not known whether SKP2 plays a role in the development of T-ALL. Here, we determined that SKP2
function is relevant for T-ALL leukemogenesis, whereas is dispensable for T-cell development. Targeted inhibition of SKP2 by
genetic deletion or pharmacological blockade markedly inhibited proliferation of human T-ALL cells in vitro and antagonized
disease in vivo in murine and xenograft leukemia models, with little effect on normal tissues. We also demonstrate a novel feed
forward feedback loop by which Notch and IL-7 signaling cooperatively converge on SKP2 induction and cell cycle activation.
These studies show that the Notch/SKP2/p27Kip1 pathway plays a unique role in T-ALL development and provide a proof-of-
concept for the use of SKP2 as a new therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL).
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
pediatric cancer and second leading cause of childhood
death [1]. Despite marked clinical advances in the treatment
of the T-cell subtype of ALL (T-ALL), about 30% of
patients experience relapse or refractory disease, which is
associated with poor prognosis. Long-term survivors also
suffer from debilitating complications. Thus, there is a need
for innovative, curative therapeutic strategies for T-ALL, in
particular relapse and refractory T-ALL [1].
Multiple oncogenic signaling mechanisms are involved
in T-ALL, including hyperactivation of the PI3K-AKT
pathway, deletion of key cell cycle inhibitors, ectopic
expression of transcription factors, and hyperactivation of
the Notch signaling pathway [2]. Although the identiﬁcation
of activating mutations in the majority of T-ALL patients
places Notch signaling as a central player in T-cell leuke-
mogenesis in both children and adults [3, 4], its therapeutic
targeting poses signiﬁcant challenges due to its important
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function in multiple organs [5]. Thus, it would be relevant
to identify critical cell-context restricted downstream med-
iators of Notch, that could be targeted.
Previous studies in our laboratory demonstrated that Notch
activation drives transcriptional activation of Skp2, promoting
rapid cell cycle entry in myeloid cells [6]. SKP2 (S-phase
kinase-associated protein 2) is the F-box protein of the E3
ubiquitin ligase complex and is responsible for targeted
recognition and degradation of various cyclin-dependent
kinases inhibitors (CKI), such as p21Cip1, p27Kip1, and p57Kip2
[7]. Thus, SKP2 is the major ubiquitin ligase that controls
abundance of cell cycle regulatory proteins at the G1–S
transition. SKP2 inactivation induces CKI accumulation and
cell cycle arrest in cells and enhances hematopoietic stem cell
(HSC) quiescence in vivo [8]. Conversely, SKP2 over-
expression results in rapid cell cycle entry and is frequently
associated with poor prognosis in cancers, including leuke-
mia and lymphoma [9]. Indeed, the SKP2 target p27Kip1 is a
critical regulator of T-cell proliferation; its accumulation is
critical for restraining cell cycle at steady state, whereas
its degradation is necessary for cell cycle entry in response to
IL-7 and other cytokines [10–12]. Given the relevant role of
p27Kip1 in T-cells and the converging effects of Notch and
mitogenic stimuli on SKP2, we sought to determine the role
of SKP2 in T-ALL leukemogenesis.
Here we show that genetic ablation of Skp2 increases
survival and signiﬁcantly delays T-ALL progression
in vivo, and that pharmacological blockade of SKP2 inhi-
bits proliferation of human T-ALL cells. Taken together,
our data support the rationale for the development of SKP2
inhibitors as therapeutic agents for T-ALL.
Material and methods
Mice
Twelve-week-old C57BL/6J Skp2−/− mice backcrossed
[8, 13]; Mx1CreRbpjlox/lox mice [14]; 8-week-old B6.SJL-
PtrcaPep3b/BoyJ (BoyJ; CD45.1), 20-week-old NOD/SCID
and NSG (NOD scid gamma) mice were used as recipients
for transplants (similar numbers of female/male were used).
Mouse care and experimental procedures were performed in
accordance with established institutional guidance and
approved protocols of the Institutional Animal Care and
Use Committees at Indiana University and City of Hope.
Retroviral transduction, primary mouse leukemias,
and xenograft models
Primary mouse leukemias were generated by retroviral
transduction/transplantation approach [15]. Viral
supernatant containing MSCV-GFP, MSCV-ICN/GFP, or
MSCV-ΔEGFΔLNRΔP-GFP constructs [16] were used
to transduce lineage negative (Lin−) progenitors from 12-
week-old Skp2+/+, Skp2+/−, and Skp2−/− CD45.2 mice.
2.5 × 104 GFP+ cells/mouse admixed with 105 protective
BM cells from C57BL/6J (CD45.2) were transplanted into
lethally irradiated (12 Gy) BoyJ CD45.1. Engraftment, GFP
positivity, and T-cell content were evaluated at 2-week
intervals in the PB. For secondary transplants, 0.5 × 106
leukemic cells from primary transplants admixed with 105
protective BM cells from C57BL/6J were transplanted into
lethally irradiated BoyJ; CD45.1.
Xenograft models were generated by transplanting 3 ×
106 TAIL7-ICN/GFP cells into NSG mice. Mice were
evaluated weekly for blast content and disease progression.
SKP2 inhibitors
The SKP2 inhibitor C1 [17] and C25 [18] (MedChemEx-
press), were used to inhibit SKP2 at concentrations from
0–80 μM. IC50 dose (C1: 2.5 µM, C25: 30 µM) was used
for cell cycle, apoptosis, and western blot analysis.
For xenografts models, C25 compound was synthesized
by the Medicinal Pharmacy Core at COH. C25 was dis-
solved in sunﬂower oil and administered 3 days/week for
4 weeks by oral gavage (50 mg/kg).
Bioinformatic analysis
Skp2 expression in mouse thymic and peripheral T-cell
populations was performed with data from the Immunolo-
gical Genome Project [19].
RNA-sequencing data for B-ALL, ETP-ALL, and T-ALL
was taken from TARGET, GSE42328, and GSE57982.
Additional experimental methods and details are pro-
vided in Supplementary Materials, including a list of anti-
bodies and primers used (Table S1 and S2, respectively).
Results
SKP2 is dispensable for T-lymphoid development in
mice
We have previously shown that Notch activation can
directly regulate cell cycle entry by inducing p27Kip1
degradation via expression of the E3 ubiquitin ligase com-
plex subunit SKP2 [6]. Given the critical role of p27Kip1 in
timing cell cycle entry during T-cell development [20], we
assessed the role of SKP2 in T-cell differentiation. Analysis
of Skp2 transcripts in different mouse organs revealed a
signiﬁcant expression of Skp2 in bone marrow (BM) and
thymus (Fig. S1A, left panel). In primary thymocytes, Skp2
expression was dynamically regulated during thymocyte
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development, with higher levels of expression associated
with high proliferative status, especially at post-β-selection
double negative (DN; CD4−CD8−) stages, DN3B and
DN4; and the immature CD8+ single positive (ISP) stage
(Fig. S1A; right panel; reviewed in [21]). Given the premise
that p27Kip1 downregulation is required for T-cell differ-
entiation from DN to double positive (DP; CD4+CD8+)
[22], and that loss of SKP2 results in p27Kip1 accumulation
and cell cycle arrest [13], we anticipated that absence of
SKP2 would compromise thymocyte differentiation in Skp2
null mice. Surprisingly, despite efﬁcient deletion of Skp2 in
the hematopoietic tissues ([13]; Fig. S1B), Skp2−/− mice
exhibited frequencies of DN and DP comparable with
Skp2+/+ mice (Fig. 1a and S1D), showed normal sized
thymus, and had similar numbers of total thymocytes
(Fig. S1C). Thymocyte cell cycle activity was also com-
parable in Skp2−/− and Skp2+/+ mice across various devel-
opmental stages (Fig. 1b). Mature lymphoid populations in
the spleen of Skp2+/+ mice exhibited Skp2 expression but no
signiﬁcant differences in total numbers of CD3+, γδ, and
NK1.1 lymphocytes were found in absence of Skp2,
although a trend for decrease was observed (Fig. S1E, F).
Interestingly, our analysis of T-cell proliferative responses to
common mitogenic signals showed that Skp2−/− mature
T-cells exhibited markedly impaired responses to CD3
plus CD28, and to IL-7 stimulation (Fig. 1c), highlighting
the importance of SKP2 in the cell cycle entry induced
by CD28 co-stimulation, as previously reported [23].
Taken together, these data show that SKP2 expression
is dispensable for T-cell development while it may be
required in mature cells to fully respond to mitogenic
stimulation.
SKP2 expression in thymocytes is upregulated by
Notch signaling activation
Next, we deﬁned the relationship between Notch and Skp2
expression in thymocytes. Skp2 expression was signiﬁcantly
reduced, although not completely abrogated, in thymocytes
freshly isolated from mice lacking Notch downstream
DNA-binding transcriptional factor RBPJ (Rbpj−/−;
Recombination signal Binding Protein for immunoglobulin
kappa j region; Fig. 2a). Similarly, expression of Skp2 in
Rbpj+/+ thymocytes was signiﬁcantly decreased but not
completely abrogated by pharmacological inhibition of
Notch signaling by a γ-secretase inhibitor in vitro (GSI;
Fig. 2b). Indeed, while GSI treatment almost completely
inhibited expression of additional Notch targets Hey1 and
Deltex (86% and 92% inhibition, respectively), it inhibited
only 40% expression of Skp2, suggesting that other path-
ways may contribute to Skp2 expression at physiological
state. Of note, a similar pattern of response for SKP2 and
Fig. 1 Impact of SKP2 depletion on normal lymphopoiesis. a Flow
cytometry analysis of thymic subsets in Skp2+/+ and Skp2−/− mice.
Percentage of DN, DP, CD4-SP, and CD8-SP cells within the whole
thymus and of DN1-4 within the DN subpopulation; n= 6 (Skp2−/−)
and n= 9 (Skp2+/+) in three independent experiments. b Percentage of
cells in S-phase measured by BrdU incorporation in indicated T-cell
subsets in Skp2+/+ and Skp2−/− thymocytes; n= 4 (Skp2−/−) and
n= 7 (Skp2+/+) in two independent experiments. c Naive T-cells from
Skp2+/+ and Skp2−/− mice stained with CFSE (10 µM) were activated
with anti-CD3 (2 µg/mL) and anti-CD28 (0.5 µg/mL) for 2 days (left
panel). On day 3, an equal number of cells were CFSE stained and
further treated for 72 h with 5 ng/ml of IL-7 (right panel). Black and
red or gray lines show CFSE dilution in the Skp2+/+ and Skp2−/− T-
cells, respectively. Solid or dashed histograms show equal loading/
Time 0 of the CFSE dye (representative experiment, n= 3). In bar
graphs, results are shown as average ± SD
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL
other Notch targets was also observed when GSI was used
in vivo (Fig. S2A).
Although Skp2 expression was moderately inﬂuenced by
Notch inhibition, it was greatly affected by Notch activa-
tion. Following 4 days in culture, Skp2 expression in
Rbpj+/+ thymocytes dropped to the same levels observed in
Rbpj−/− thymocytes when in absence of Notch stimulation,
but it was strongly upregulated when in presence of
Delta1 (Dll1) ligand (sixfold increase; Fig. 2c; left panel).
Accordingly, cell cycle analysis showed a sharp increase
(up to fourfold) in percentage of Rbpj+/+ thymocytes
progressing into S-phase when exposed to Dll1 ligand
(Fig. S2B). Of note, some levels of Skp2 expression and
mitogenic response were preserved in Rbpj−/− thymocytes
in the absence of Notch signaling (Fig. 2c and S2B), sug-
gesting Notch-independent Skp2 regulation. As the culture
conditions included IL-7, a cytokine required for T-cells
survival and proliferation and involved in p27Kip1 regulation
[24–26], we measured the distinct contribution of IL-7 and
Notch activation to Skp2 expression. Skp2 expression and
thymocyte mitogenic activity were sustained above basal
level by IL-7 alone and were signiﬁcantly upregulated in the
presence of Notch signaling (Fig. 2c; right panel). Overall,
these observations show that Skp2 expression is robustly
upregulated by activation of Notch signaling in combination
with IL-7 stimulation. Ultimately, the cooperative effect of
Notch and IL-7 may have a critical role in leading to
uncontrolled proliferation and leukemia transformation.
Oncogenic Notch upregulates SKP2 expression in
T-ALL cells in vivo
Given the role of Notch in T-cell leukemogenesis and
the converging effects of Notch and IL-7 on SKP2, we
investigated the role of SKP2 in T-ALL leukemogenesis
in vivo by using a Notch-induced T-cell leukemia mouse
model. Overexpression of constitutively active intracellular
form of Notch1 (ICN) in hematopoietic stem/progenitor cells
(HSPCs) induces T-ALL with 100% penetrance [16, 27].
We transduced wild-type (WT; Skp2+/+) HSPCs with a ret-
roviral construct containing ICN (MSCV-ICN/IRES/GFP;
herein referred as ICN) or vector control (MSCV/IRES/GFP;
herein referred as vector), and transplanted them into syn-
geneic WT mice. As anticipated, recipients showed accu-
mulation of ICN-GFP+ and CD4+ CD8+ DP T-cells in BM
(Fig. S3A, B) associated with rapid increase of white blood
cell (WBC) counts, DP T-cells in peripheral blood (PB), and
splenomegaly (Fig. S3C, D). HSPCs overexpressing ICN
(Fig. S3E) showed a 5-fold and 2.5-fold increase in Skp2
expression in BM and spleen, respectively, compared with
HSPCs transduced with vector control (Fig. 3a). In these
cells, Skp2 upregulation was associated with direct binding of
Notch1/RBPJ complex to the endogenous Skp2 promoter
(Fig. 3b and S3F).
Loss of SKP2 antagonizes Notch-induced leukemia
Next, we overexpressed ICN in HSPCs lacking SKP2
and transplanted them into syngeneic WT mice. We com-
pared cohorts of mice transplanted with Skp2+/+, Skp2−/−,
and Skp2−/+ HSPCs overexpressing ICN-GFP. Homing and
engraftment of Skp2−/− cells to BM is similar to Skp2+/+
cells [8]. As expected, animals transplanted with Skp2+/+
ICN cells developed full-blown T-ALL by week 8 post
transplant, whereas mice that received Skp2−/− ICN cells
exhibited WBC counts similar to animals transplanted with
vector control and low levels of donor T-cells in the PB
(Fig. 4a and S4A). Absence of SKP2 in ICN cells was
Fig. 2 Activation of Notch and IL-7 signaling pathways cooperate to
heighten SKP2 expression. a Fold change for Skp2 mRNA expression
measured by qRT-PCR in fresh population of total thymoctes har-
vested from Rbpj+/+ or Rbpj−/− mice (Day 0). Results are indicated as
average ± SE; n= 6 (Rbpj−/−) and n= 9 (Rbpj+/+) in two independent
experiments. b Fold change for Skp2, Deltex, and Hey1 mRNA
expression measured by qRT-PCR in total thymocytes at 24 h of co-
culture with OP9-Dll1 cells in the presence of DMSO or 5 µM GSI;
each group n= 4. c Fold change for Skp2 mRNA expression measured
by qRT-PCR in two independent experiments. Left panel: Rbpj+/+ or
Rbpj−/− total thymocytes population at 4 days of co-cultured with OP9
or OP9-Dll1 cells in the presence of IL-7 (25 ng/ml); n= 3 (Rbpj−/−)
and n= 4 (Rbpj+/+). Right panel: total thymocytes at 24 h of co-
culture with OP9 or OP9-Dll1 cells in the absence or presence of IL-7
(25 ng/ml); n= 3 (OP9) and n= 4 (OP9-Dll1). All results are
expressed as average ± SD. *p < 0.05, **p < 0.01, ***p < 0.005 by
t-test or one-way ANOVA
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associated with increased levels of p27Kip in most cases
(Fig. S4B), and correlated with a 50% reduction in cell
cycle activity (Fig. 4b), which occurred mostly at early G1-
S phase transition (Fig. S4C).
Long-term follow-up of transplanted mice showed that
all recipients of Skp2+/+ ICN cells were terminal by week
12, whereas T-ALL development was signiﬁcantly delayed
in recipients of Skp2−/− ICN cells, with 50% survival at
week 12 (Fig. 4c left panel). Notably, 29% of Skp2−/− ICN
recipients did not show signs of leukemia at week 30 and
survived more than 1 year without evidence of disease.
Interestingly, loss of one copy of Skp2 did not confer any
survival advantage to recipients of heterozygous Skp2+/−
ICN cells and these mice developed T-ALL with kinetics
similar to recipients of Skp2+/+ ICN cells (Fig. 4a, c, S4A).
As the ICN allele used above models the rare t(7:9)
translocation and encodes a potent transcriptional transac-
tivator [16], we tested the Notch1ΔEGFΔLNRΔP construct
(deﬁned here as N1ΔEGF), which better models the
leukemia-associated NOTCH1 mutations disabling the
negative regulatory region and PEST domain commonly
seen in patients, and exhibits a weaker transcriptional
activity than ICN [28]. We observed that Skp2−/− ΔEGF
recipient mice had a greater survival probability (50%, 95%
CI: 10–90) than Skp2−/− ICN recipients (29%, 95% CI:
5–52) at 32 weeks post transplant (Fig. 4c right panel and
S4D).
SKP2 deletion leads to early exhaustion of ICN-GFP
populations
As shown in Fig. 4c, among all recipients of Skp2−/− ICN
cells, one group (71%) did not survive longer than 32 weeks
from transplant, whereas one group (29%) remained healthy
and survived at long-term (scheme in Fig. 4d). To exclude
the possibility that some Skp2−/− ICN recipients did not
survive because of low BM engraftment, we measured the
levels of CD45.2+ donor cells in the PB at different times
post transplant. As shown in Fig. S5A, the engraftment of
CD45.2 donor cells was robust and similar in all Skp2+/+
and Skp2−/− groups. To exclude the possibility of insufﬁ-
cient ICN expression by SKP2−/− transduced cells in the
Skp2−/− ICN recipients that survived, we measured ICN
expression in BM cells after transduction and soon after
transplant. Prior to transplant, transduced Skp2−/− HSPC-
ICN, validated for Skp2 deletion (Fig. S5B), showed
expression of ICN comparable with transduced Skp2+/+ and
Skp2+/− HSPCs (Fig. S5C). In addition, BM sampling
performed in an independent cohort showed that a similar
number of Skp2+/+, Skp2−/−, and Skp2−/+ ICN-GFP+
transduced cells (~9 × 103) engrafted in recipients at
2.5 weeks from transplant (Fig. S5D). To examine more
closely the characteristics of the recipients of Skp2−/− ICN
cells, we separated and analyzed independently the group
that survived and the group that did not survive (Fig. 4d),
herein indicated as Skp2−/−ICNs and Skp2−/−ICNns,
respectively. WBC counts and frequency of ICN-GFP+
cells were similar in the PB of Skp2−/− ICNns and Skp2−/−
ICNs recipients and followed the kinetics of Skp2+/+ vector
control mice until week 6 of transplant (Fig. 4e). At this
point, despite comparable initial levels of ICN expression
(Fig. S5C, D) and low percentages of ICN-GFP+ in the PB
(average 0.3% vs. 0.2%), Skp2−/− ICNns recipients exhib-
ited increasing levels of WBCs and of T-cell leukemia
blasts, whereas Skp2−/− ICNs recipients showed WBC
Fig. 3 SKP2 expression is upregulated in vivo in the Notch-induced
T-ALL model. Lin− cells from C57Bl/6 mice (CD45.2) were transduced
with MSCV-GFP (Vector) or MSCV-ICN1-GFP (ICN) constructs.
2.5 × 104 ICN/GFP+ cells were transplanted into lethally irradiated BoyJ
(CD45.1). Recipients were analyzed for: a Fold change for human Skp2
mRNA expression measured by qRT-PCR in the BM (left panel; n= 5)
and Sp (right panel; n= 6 (vector) and n= 10(ICN)). b CHIP assay.
DNA isolated from the thymus of mice transplanted with ICN-GFP+
cells was immunoprecipitated with anti-Notch1 (N1) or anti-Jagged1
(irrelevant) antibodies Top panel: Scatter graph shows fold changes in
SKP2 promoter enrichment measured by qRT-PCR (each group n= 3).
Bottom panel: schematic representation of the Notch/RBPj binding sites
within the mouse Skp2 promoter. All results are from two independent
experiments. In scatter plots average is shown by a horizontal line.*p <
0.05, **p < 0.01, ***p < 0.005 by t-test
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counts and T-cell percentages comparable with the control
group (Fig. 4e). ICN transcripts were no longer detected in
BM of Skp2−/− ICNs recipients at 1 year from transplant,
whereas elevated ICN transcripts were detected in BM of
leukemic Skp2−/− ICNns recipients at time of sacriﬁce when
moribund (Fig. S5E). Notably, Skp2−/− ICNs recipients
exhibited normal hematopoiesis and did not show signs of
leukemia at 1 year from transplant. This outcome was
validated by the presence of normal myeloid and B-cells,
normal frequency of T-cells and LSK cells in the BM
Fig. 4 Loss of SKP2 attenuates Notch-induced leukemia. Lin− cells
from Skp2+/+, Skp2+/−, or Skp2−/− (CD45.2) mice were transduced
with MSCV-GFP (Vector), MSCV-ICN1-GFP (ICN), or MSCV-
N1ΔEGFΔLNRΔP-GFP (N1ΔEGF) constructs. 2.5 × 104 GFP+ cells
were transplanted into lethally irradiated BoyJ (CD45.1) recipients
(three independent experiments) and were analyzed for: a Percentage
of DP T-cells in in gated CD45.2+ donor cells in PB. Skp2+/+ Vector
(n= 6), Skp2+/+ ICN (n= 10), Skp2+/− ICN (n= 10) and Skp2−/−
ICN (n= 6); (average ± SE). b Bar graph show BrdU incorporation in
GFP+ cells from Skp2+/+ ICN (n= 5) and Skp2−/− ICN (n= 3) in BM
and spleen populations analyzed in recipients at week 8 from
transplant. c Kaplan–Meier survival curve. Control cohorts include:
Skp2+/+ Vector group (n= 10; green solid line) and Skp2−/− non-
transduced and Skp2−/− Vector group (n= 8; dark green dashed line);
all these groups behaved identically. Experimental cohorts: in left
panel include Skp2+/+ ICN (n= 19; blue line), Skp2−/+ ICN (n= 14;
purple line) and Skp2−/− ICN (n= 14; red line); in right panel includes
Skp2+/+ N1ΔEGF (n= 6; blue line) and for Skp2−/− N1ΔEGF (n= 6;
red line). d Scheme representing the survival percentages of Skp2−/−
ICNns (solid red) and Skp2−/− ICNs (dashed red). Mice within Skp2−/−
ICN genotype were distributed in two groups based on their survival,
here called Skp2−/− ICNns (no survivors; 71%) and Skp2−/− ICNs
(survivors; 29%). Recipients of all genotypes (in three independent
experiments), were analyzed at full-blown disease or at 1 year from
transplant. e Line graph in left panel represents counts of WBC in the
PB of recipient mice at the time points indicated. Line graph in right
panel represents percentage of GFP+ cells gated on CD45.2+ cells in
the PB of recipient mice at the time points indicated (average ± SE).
Skp2+/+ Vector (n= 6), Skp2+/+ ICN (n= 10), Skp2−/− ICNns (n= 6),
and Skp2−/− ICNs (n= 3). Arrows indicates point of divergence
between Skp2−/− ICNs and Skp2−/− ICNns. All results are expressed as
average ± SD unless otherwise indicated. *p < 0.05, **p < 0.01, ***p
< 0.005 by two-sample t-test, t-test or log-rank test
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(Fig. S6A), absence of splenomegaly and of leukemic
inﬁltrates in spleen, liver, and bone, and tissue organization
similar to matched control mice (Fig. S6B, C). In contrast,
all Skp2−/− ICNns recipients developed leukemia and
showed PB, BM, and tissue involvement similar to that
observed in recipients of Skp2+/+ ICN cells; however, they
exhibited a delayed onset of disease and slower kinetics
of progression (Fig. 4c–e), which persisted in secondary
transplants (Fig. S6D).
Overall, these data demonstrate that absence of SKP2 can
prevent leukemia development by driving exhaustion of
Skp2−/− ICN population in some recipients.
Gene expression proﬁling reveals a Notch/IL-7/
SKP2 signature in T-ALL samples
SKP2 upregulation results in rapid cell cycle entry and is
frequently associated with poor prognosis in cancers
[18, 29], including leukemia and lymphomas [9, 30]. We
performed a bioinformatic analysis of publicly available
transcriptome data and found that patients with T-ALL
exhibited higher expression of Skp2 in comparison with
B-ALL patients (Fig. 5a, far left panel). Not surprisingly,
given the high frequency of Notch activating mutations
[3, 26] and the role of IL-7 in T-ALL, this proﬁle was
associated with increased Notch activation and increased
availability to respond to IL-7, as indicated by higher
average expression of Notch1 and its targets Hes1 and
IL-7r, respectively (Fig. 5a, left, right, and far right panels).
In light of these data, we performed principal component
analysis using Skp2 expression in combination with other
Notch and IL-7 signaling downstream targets (23 genes;
Fig. S7A). We found that this combination was sufﬁcient to
separate the identity of T-ALL from B-ALL samples, as
seen when using the global transcriptome (Fig. 5b).
Collectively, these ﬁndings suggest a prominent role of the
Notch/IL-7/SKP2 axis in T-ALL biology.
Pharmacological blockade of SKP2 inhibits human
T-ALL in vitro and in vivo
Next, we investigated the effects of SKP2 pharmacolo-
gical blockade on human T-ALL cells by using the small
molecule SKP2 inhibitor, C1, developed for its ability to
block protein–protein interaction between SKP2 and
p27Kip1 [17]. First, we validated C1 compound’s selec-
tivity by showing that C1 inhibited cell growth of Skp2+/+
without affecting signiﬁcantly Skp2−/− murine embryonic
ﬁbroblasts (Fig. S8A). C1 was very effective in inhibiting
murine primary Skp2+/+ ICN T-ALL cells (IC50: 0.62 µM)
while showing little toxicity on primary murine BM cells
(Fig. S8B–D). Treatment of several human T-ALL cell
lines, all exhibiting elevated SKP2 levels (Fig. S8E),
showed a signiﬁcant dose-dependent inhibition of cell
proliferation in cell lines with high Notch activation and
also in cell lines established from high-risk and relapsed
patients, which have little or no Notch signaling, such as
CEM and Loucy (Fig. 6a), suggesting that SKP2 inhibi-
tion is effective also in Notch-independent highly pro-
liferative leukemia subtypes.
Fig. 5 A Notch/SKP2/IL-
7 signature deﬁnes human
T-ALL samples. a Expression
of SKP2, NOTCH1, HES1, and
IL-7r transcripts (CPM) across
primary T-ALL, ETP-ALL, and
B-ALL cases (n= 17, 34, and
154, respectively). b Principal
component analysis showing the
distribution of primary T-ALL,
B-ALL, and AML samples
according to their whole
transcriptome (left panel) or to
the expression of 23 key genes
involved in NOTCH and IL-7
signaling pathways (right panel)
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Fig. 6 SKP2 blockade by small molecule inhibitors reduces pro-
liferation of T-ALL in cell lines, primary cells, and in vivo in a
xenograft model of T-ALL. Viability assays for the C1 inhibitor were
performed at 96 h for cell lines and 48 h for primary cells. DMSO was
used as vehicle control in all experiments. a Percentage viability of
human T-ALL cell lines treated with increasing doses of the SKP2
inhibitor C1 (average ± SE). SupT1, HBP-ALL (n= 4), and all other
cell lines (n= 6) in three independent experiments. b Percentage
viability of primary T-ALL patient cells treated with increasing doses
of the SKP2 inhibitor C1 (three patients samples, two independent
experiment). c Top panel: percentage viability of TAIL7 cells treated
with increasing doses of the SKP2 inhibitor C1 (n= 6 in three inde-
pendent experiments). Bottom panel: percentage of cells in S-phase
measured by BrdU incorporation and percentage of apoptotic cells
measured by Annexin V in TAIL7 cells treated for 48 h with 2.5 µM
C1 or DMSO; n= 4. d Percentage of cells in S-phase measured by
BrdU incorporation and percentage of apoptotic cells measured by
Annexin V in TAIL7 cells treated for 48 h with 30 µM C25 or DMSO
as vehicle control (average ± SD); n= 3. e Western blot (top) and
densitometry analysis (bottom) of SKP2, p27Kip1, and β-Actin protein
levels in TAIL7 cells treated with DMSO, 2.5 µM C1 and 30 µM C25
for 48 h; four independent experiments. f Immunoﬂuorescence images
show accumulation and localization of p27kip1 (red) in the nucleus
(blue) in TAIL7 cells following treatment with 30 µM of C25 or
DMSO for 48 h (representative of three independent experiments).
g Line graph shows average percentage of ICN-GFP+ blasts in the PB
of each recipient mouse at the time points indicated. End point is the
last point indicated in the graph. h Kaplan–Meier survival curve. All
experiments are shown as average ± SD unless otherwise indicated.
**p < 0.01, ***p < 0.005 by t-test. p= 0.009 by long rank test
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As IL-7 contributed to Skp2 expression and cooperated
with Notch activation in inducing cell cycle entry in healthy
murine thymocytes (Fig. 2c; right panel), we validated these
results in the IL-7-dependent T-ALL cell line, TAIL7 [31],
and in primary T-ALL cells, which are responsive to IL-7
for survival and proliferation. A time-dependent increase
of SKP2 levels, associated with signiﬁcant reduction in
p27Kip1 levels, was observed in TAIL7 cells following sti-
mulation with IL-7 (Fig. S8F), highlighting the conserva-
tion of the IL-7/SKP2/p27Kip1 axis from mouse to human
T-cells. We observed that C1 treatment signiﬁcantly
inhibited cell viability of primary T-ALL cells (Fig. 6b;
IC50: 1.72 µM) and of TAIL7 cells (Fig. 6c; IC50: 2.4 µM)
even in the presence of high-dose IL-7. This effect was also
associated with a signiﬁcant increase in the percentage of
apoptotic cells (Fig. 6c). The effects of SKP2 pharmaco-
logical blockade were corroborated by using an additional
SKP2 inhibitor, the C25 compound [18]. C25 inhibited
TAIL7 viability in a dose-dependent manner (Fig. S9A) and
it was effective in inducing cell cycle arrest and apoptosis
(Fig. 6d) as well as leading to accumulation and localization
of p27Kip1 in the nucleus (Fig. 6e, f).
Currently available SKP2 inhibitors have limited phar-
macological properties and their use in vivo poses numer-
ous challenges. To provide a proof-of-concept for the
antileukemic effect of SKP2 inhibitors, we treated leukemic
mice with the C25 compound, which was previously tested
in vivo in a solid tumor model and showed some efﬁcacy
[18]. We transplanted TAIL7-ICN cells in NSG mice, as a
more aggressive and traceable model, and delivered C25
treatment as monotherapy for 4 weeks, starting at evidence
of circulating blasts (Fig. S9B). While the leukemic mice
treated with vehicle succumbed to the disease at week 7,
mice treated with C25 exhibited prolonged survival
(Fig. 6g) and showed a signiﬁcant decrease in blasts in PB
and spleen (Fig. 6h and S9C–E). Collectively, these results
show that SKP2 blockade impairs the growth of human
T-ALL cells in vitro and in vivo and argue for development
of SKP2 inhibitors with better pharmacological properties.
Discussion
SKP2 (S-phase kinase-associated protein 2) is the F-box
protein of the SCF E3 ubiquitin ligase complex that targets
proteasome-dependent degradation of many CKIs [32–35], in
particular phosphorylated p27Kip1, promoting rapid cell cycle
entry in many cell types. In this study, we addressed the role
of SKP2 in normal and malignant T-cells and showed that
SKP2 is dispensable for normal thymocyte development but
plays an active role in T-cell leukemogenesis.
We previously discovered that SKP2 is a direct target of
Notch [6], which is required for T-cell development and is
involved in T-cell leukemogenesis [36, 37]. The transcrip-
tional program activated by Notch signaling is necessary for
T-cell differentiation, but requires accurate regulation of cell
proliferation and timed downregulation of p27Kip1 [20, 22].
We postulated that SKP2, being a key cell cycle regulator at
the intersection of Notch and p27Kip1, would play a critical
role in T-cell differentiation. Surprisingly, we found that
although Notch signaling contributes signiﬁcantly to T-
lymphocytes cell cycle entry by inducing Skp2, Skp2
expression appears to be dispensable for T-cell develop-
ment. The dispensable role of SKP2 in T-cell development
is in striking contrast with the critical role of another
positive cell cycle regulator, cyclin D3, which loss severely
impairs lymphoid development [38]. It is possible that while
deletion of cyclin D3 completely disables CDK4 and CDK6
complexes, effectively impeding cell cycle progression, loss
of SKP2 in thymocytes does not result in the sufﬁciently
elevated levels of p27Kip1 required to block all cyclin/CDK
complexes (CDK2, 4 and 6). Our results are in agreement
with reports showing that coupling of proliferation and
differentiation in T-cells is compromised only in transgenic
mice overexpressing high, but not intermediate, levels of
p27Kip1 [22], and that loss of p27Kip1 only partially rescues
the cell cycle block induced by cyclin D3 deletion [39].
Taken together, these observations indicate that developing
thymocytes may possess regulatory mechanisms that allow
cell cycle progression notwithstanding increased levels of
p27Kip1. Our data also suggest that these compensatory
mechanisms may not be active in mature T-cells stimulated
by mitogenic factors, as shown by impairment of cell pro-
liferation in mature Skp2−/− T-cells following stimulation
with CD28 and IL-7. The mechanisms that inﬂuence these
two distinct outcomes are unclear and warrant further
investigation.
In this study, Notch inhibition by genetic deletion or
pharmacological blockade showed that Notch signaling con-
tributes only partially to maintenance of basal Skp2 levels,
while activation of Notch by high density Dll1 ligand or
constitutive active Notch (ICN) upregulates substantially Skp2
expression. This observation raises the possibility that
supraphysiological stimulation of Notch1 signaling is required
to license new oncogenic drivers that would not be sufﬁcient
or accessible with lower, physiological levels of Notch sig-
naling. This is clinically relevant as clinical trials have shown
that Notch inhibitors are too toxic due to Notch requirement
in essential physiological functions. These observations raise
the possibility of speciﬁcally targeting Notch in cancer by
selectively disabling its critical downstream target genes, such
as SKP2.
To determine the impact of SKP2 on leukemogenesis, we
have used a Notch-induced murine leukemia model driven by
the ICN allele, which models the rare t(7:9) translocation and
is a potent transcriptional transactivator. It is noteworthy that
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in this model of aggressive T-ALL, SKP2 deletion prevented
leukemia development in ~30% of mice, which were disease-
free for the entire period of the follow-up (>1 year), and
delayed onset of leukemia in two thirds of the transplanted
cohort. Survival was further prolonged when Skp2 was
deleted in the context of a weaker form of activated Notch.
Genetic deletion of Skp2 in presence of ICN resulted in
p27Kip1 accumulation and reduction of cell cycle activity
in lymphoblasts, and correlated with various degrees of dis-
ease inhibition. The robust antileukemic effect of SKP2
deletion on some mice raises the possibility that SKP2 exerts
tumor suppressive effects also through additional mechan-
isms other than cell cycle. Indeed, a role of SKP2 in
regulating cell metabolism has been recently highlighted in
breast cancer [40] and warrants future studies during
leukemogenesis.
Interestingly, our experimental design revealed that despite
equivalent deletion of SKP2 and similar expression of ICN,
Skp2−/− ICN cells were extinguished in some recipients while
persisting and leading to leukemogenesis in others. This
outcome did not seem to depend on the levels of ICN or
SKP2, and it is likely inﬂuenced by different factors,
including microenvironmental cues, immune responses, and
other stochastic events. Previous studies show that supra-
physiological levels of Notch signals gradually deplete
HSPCs over weeks [41]. Thus, Notch-activated HSPCs seem
to have only a limited window of time to initiate T-ALL. It is
possible that during this window, in the context of SKP2
absence, some incipient leukemia cells were able to access
SKP2-independent mechanisms to fully transform into T-
ALL. Future studies are necessary to clarify the mechanisms
that can override the impact of the cell cycle inhibitory effects
of SKP2 deletion in T-ALL blasts and to determine the
contribution of non-cell autonomous factors, such as BM
microenvironment and the immune response. Given the
potential role of SKP2 in cancer stem cells [18], elucidating
SKP2-dependent versus SKP2- and p27Kip1- independent
mechanisms will provide insights into the mechanisms of
cancer cells resistance and relapse.
Our data show that IL-7 signaling synergizes with Notch
activation in inducing Skp2 expression and cell cycle acti-
vation in thymocytes and human T-ALL. Accordingly, Il-
7Rα is an important downstream target gene of Notch
[42–44]. It was previously reported that IL-7 stimulation
induces p27Kip1 degradation and cell cycle entry in human
T-ALL [10], and that SKP2 can mediate p27Kip1 degradation
upon IL-7 stimulation in murine thymocytes [25]. Our
observations uncover a previously unrecognized role for
SKP2 as a point of convergence between Notch and IL-7
pathways in T-ALL. Not surprisingly, Skp2 expression has
been found elevated in lymphoid malignancies and in
T-ALL cell lines [9, 11]. This feature may speciﬁcally reﬂect
the biology of T-ALL blasts, in which high frequency of
activating Notch mutations and dependence on IL-7 sig-
naling cooperate in regulating Skp2 expression and cell cycle
activation, generating a T-ALL speciﬁc molecular signature.
Indeed, a combination of a limited number of genes [37],
which includes Skp2 plus other Notch and IL-7 target genes,
is sufﬁcient to separate the identity of T-ALL from B-ALL,
which also express Skp2, albeit at lower levels.
In our study, SKP2 inhibitors were effective in reducing
viability of human T-ALL cell lines and primary T-ALL
samples in vitro even in the presence of the protective effect
of IL-7. Furthermore, despite the pharmacological limita-
tions of C25 SKP2 inhibitor used in this study, signiﬁcant
reduction of tumor burden was observed with a short
monotherapy regiment in an aggressive xenograft model of
T-ALL.
Although current frontline therapies have demonstrated
efﬁcacy in T-ALL, 25–30% of patients remain refractory
to therapy or undergo disease relapse. Furthermore, cur-
rent therapies in pediatric patients have long-term toxi-
cities. Thus, the identiﬁcation of new and less toxic
therapeutic approaches is an unmet clinical need. SKP2
inhibitors with better pharmacological proﬁle have the
potential to be highly effective in T-ALL, and likely in
other cancers, as SKP2 expression has been shown to
correlate with progression in different tumors and blood
malignancies (review in [45]). Other possible advantages
of SKP2 as a therapeutic target in cancer include the
potential for selective targeting compared with the use of
other signaling inhibitors with broader activities or higher
toxicity, such as the proteasomal inhibitor bortezomib
[46] or the CDK4/6 inhibitors [47]. One can predict that
selective SKP2 inhibitors would have low toxicity since
Skp2-knockout mice are healthy. Therefore, increasing
efforts are necessary to develop more effective SKP2
inhibitors that can be used in preclinical studies and
clinical trials. Our present study shows that T-ALL cells
rely on the SKP2/p27Kip1 axis more heavily than normal
T-cells for cell growth, and that SKP2 inhibition antag-
onizes T-cell leukemogenesis while resulting in little
toxicity to normal cells, thus providing a proof-of-concept
for targeting SKP2 in T-ALL leukemia.
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